Navigation Links
Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
Date:3/31/2008

veloping new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, the Company's ability to obtain additional financing if required on favorable terms or at all, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com

TABLES FOLLOW

Clarient , Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenue $12,357 $8,055 $42,995 $27,723

Cost of revenue 5,993 4,469 22,304 15,566

Gross profit 6,364 3,586 20,691 12,157

Selling, general and

admi
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... developed a new microscopy technology that allows them ... higher-than-ever resolution. , Dubbed "Complementation Activated Light Microscopy" ... are an order of magnitude finer than conventional ... of biomolecules at the nanometer scale. , In ... Nature Communications , the researchers behind CALM used ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... decision to return capital to stockholders through liquidationA ... Biotechnology Value Fund, L.P. ("BVF"), today announced ... ) voted overwhelmingly to remove the existing Board ... BVF,s nominees. The vote took place earlier today ...
... Human Genome Sciences, Inc. (Nasdaq: ... 4th Annual Citi Biotech Day will be webcast and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )A ... present a corporate overview on Wednesday, April 1, 2009 ...
... BUDAPEST, Hungary, and PRINCETON, N.J., March 27 Zinsser ... collaboration agreement for product distribution in the territory of ... about partnering with Zinsser Analytic. Zinsser is a leader ... around the world," said Dr. Ferenc Darvas, president and ...
Cached Biology Technology:Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders 2Zinsser Analytic and ThalesNano Collaborate on Distributing Products 2
(Date:9/18/2014)... world, are the ideal animal in which to study ... the ocean into tens of thousands of freshwater streams ... skeleton to adapt to the new environment. , Breeding ... have turned up one of the genes that controls ... that gene,s regulation in a freshwater population is associated ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
(Date:9/17/2014)... in 2000 as an EC-FP5 four-year project, delivering its ... progress and successful participations in several EC projects, as ... Network project (EU BON), to increase the general ... to extend the general dissemination of the Fauna Europaea ... has applied its novel e-Publishing tools to prepare data ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... tungsten trioxide clusters line up molecule-by-molecule on the titanium ... raised slightly, holding forth the potential to execute catalytic ... system, a simplified version of a catalyst that would ... chemists the exact structure and reaction mechanisms of metal ...
... the leading cause of most common colds, struck two ... graft dysfunction and death. The two were part of ... significant respiratory infection from HRV in both the upper ... affects only upper airway tissue. , The research appears ...
... For years, the brain chemical dopamine has been thought of ... in a way that rewards a person or animal for ... certain drugs like cocaine and heroin amplify this effect ?an ... , Now, a new study from the University of ...
Cached Biology News:Uniform tungsten trimers stand and deliver 2Common cold virus leads to death in lung transplant patients 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 3Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 4
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
... polyclonal antibody raised against a ... Immunogen: PPP4C (NP_002711, ... partial recombinant protein with GST ... Number: NM_002720 ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Biology Products: